Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HbSC disease~* Score of 80 or lower on the AdultQLTM 3.0 Sickle Cell Disease Module, or any disease related complication, including, but not limited to, one or more pain events per year, proliferative sickle retinopathy, avascular necrosis, cholelithiasis, or any thrombotic event. If the subject has a score \>80, they may still enroll on the trial, and be analyzed for secondary endpoints. They will be excluded from analysis of the primary endpoint.~Exclusion Criteria:~* Failure to meet inclusion criteria~* Hydroxyurea usage in the last 3 months.~* Chronic RBC transfusion therapy~* Packed red blood cell transfusion in the last 3 months (temporary exclusion).~* Pregnancy, or refusal to use medically effective birth control if female and sexually active.~* Current phlebotomy therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxurea (Type: EXPERIMENTAL): Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).